Answers are grounded in this paper and cite their sources.
Interview with Dr. Peter Bach on payment approaches Medicare could consider for costly new CAR-T treatments. (07:38)Download Even if CMS concludes that CAR-T therapy provides a net benefit for Medicare patients, it could limit who can provide the therapy, require collection of further outcome data, limit coverage to clinical trials, and design a payment approach promoting price competition.
No takes yet. Share an insight, caveat, or question.
Peter B. Bach (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: